Related Experiment Video
Updated: May 13, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Pathways to implementation of serum proteomics for cancer
Madhumita Chatterjee1, Nancy K Levin, Jay P Shah
1Karmanos Cancer Institute/Wayne State University School of Medicine, Program in Molecular Biology and Genetics, Department of Pathology, 110 E. Warren, Detroit, MI 48201, USA.
Expert Opinion on Medical Diagnostics
|March 16, 2013
Summary
New proteomic and genomic technologies enable early cancer detection using multianalyte tests in body fluids. Implementation challenges include medical, commercial, and regulatory factors for these advanced diagnostic tools.
Area of Science:
- Biomarker Discovery
- Cancer Diagnostics
- Proteomics and Genomics
Background:
- Proteomic and genomic technologies allow simultaneous detection of numerous cancer biomarkers in bodily fluids.
- These advancements promise significant improvements in early cancer detection but introduce challenges in implementing multianalyte diagnostic tests.
Purpose of the Study:
- To explore the promise and challenges of implementing multianalyte cancer diagnostic tests.
- To discuss the potential impact of noninvasive diagnostic approaches on early cancer detection and clinical intervention.
Main Methods:
- Detection of serum antibodies to tumor antigens.
- Analysis of cancer-related proteins in serum.
- Identification of tumor-specific genomic alterations in plasma-free DNA.
Main Results:
- Multianalyte tests offer potential for early cancer detection through various biomarker analyses.
- Noninvasive approaches can extend presymptomatic periods for medical intervention.
Conclusions:
- The widespread adoption of multianalyte cancer tests depends on balancing medical, commercial, reimbursement, and regulatory factors.
- Successful implementation requires addressing the complexities of integrating new diagnostic devices into patient care.
